TO WHAT EXTENT ARE THE LEARNINGS FROM THE INTRODUCTION OF BIOSIMILARS IN INFLAMMATORY DISEASES TRANSFERABLE TO THE FUTURE INTRODUCTION OF BIOSIMILARS IN ONCOLOGY?

被引：0
|
作者：
Klebba, S. [1 ]
Makin, D. [1 ]
Teale, C. W. [2 ]
机构：
[1] GfK, London, England
[2] GfK, Melton Mowbray, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2321
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN245
引用
收藏
页码：A753 / A753
页数：1
相关论文
共 37 条
  • [1] Introduction and Use of "biosimilars" in the Treatment of inflammatory-rheumatic Diseases
    Lorenz, H. -M.
    Braun, J.
    Krueger, K.
    Schneider, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 (09): : 784 - 786
  • [2] Introduction and Commentary: Paving the Way for Biosimilars in Oncology
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2013, 40 (06) : S1 - S4
  • [3] Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
    Oskouei, Sonia T.
    AMERICAN JOURNAL OF MANAGED CARE, 2022, 28 (12): : S215 - S216
  • [4] Introduction and Commentary: Paving the Way for Biosimilars in Oncology, Part 3 Clinical and Economic Impact of Oncology Biosimilars
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2014, 41 (02) : S1 - S2
  • [5] Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
    Scheinberg, Morton
    Pineda, Carlos
    Castaneda-Hernandez, Gilberto
    Jose Zarba, Juan
    Damiao, Aderson
    Arantes, Luiz H., Jr.
    Jacobs, Ira
    MABS, 2018, 10 (06) : 827 - 842
  • [6] An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
    Hariprasad, Seenu M.
    Gale, Richard P.
    Weng, Christina Y.
    Ebbers, Hans C.
    Rezk, Mourad F.
    Tadayoni, Ramin
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 959 - 982
  • [7] An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
    Seenu M. Hariprasad
    Richard P. Gale
    Christina Y. Weng
    Hans C. Ebbers
    Mourad F. Rezk
    Ramin Tadayoni
    Ophthalmology and Therapy, 2022, 11 : 959 - 982
  • [8] The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease
    Severs, M.
    Oldenburg, B.
    van Bodegraven, A. A.
    Siersema, P. D.
    Mangen, M-J. J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (03): : 289 - 296
  • [9] Introduction and Commentary: Paving the Way for Biosimilars in Oncology, Part 2
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : S1 - S2
  • [10] Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe
    Agboton, Christian
    Salameh, Joseph
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 157 - 167
1234